1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,500 | 0,510 | 30.12.24 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.10.24 | IntegraGen: 2024 Half-Year Results - Sales up 6% on a Like-for-Like Basis (Excluding SeqOIA) and Profitability Maintained | 228 | Business Wire | Revenue growth for the Évry laboratory activities Restructuring and cost reduction plan implemented after cessation of services to SeqOIA in February Overall profitability remained... ► Artikel lesen | |
| INTEGRAGEN Aktie jetzt für 0€ handeln | |||||
| 18.07.24 | IntegraGen: First-Half 2024 Sales of €4.5m, up 6% on the Scope Excluding SeqOIA and Cash Position of €2.8m | 335 | Business Wire | The discontinuation of services for the SeqOIA platform mechanically led to a 20% reduction in revenues in the first half of the year. Adjusted for this base effect, growth was 6% over the period.... ► Artikel lesen | |
| 18.04.24 | IntegraGen: Annual Results 2023 - Positive EBITDA Reflecting Tight Cost Control | 366 | Business Wire | EVRY, France--(BUSINESS WIRE)--Regulatory News:
IntegraGen (FR0010908723 - ALINT - Eligible PEA PME), an OncoDNA company specializing in the genomics of cancer and rare genetic diseases, which... ► Artikel lesen | |
| 16.01.24 | IntegraGen Reports €11.8M Revenues for 2023 | 593 | Business Wire | Significant reduction of COVID-19 related activities
Growth of all other lines of business
Cash totaling €2.9m on Dec 31st, 2023
Laboratory in Évry accredited by the College... ► Artikel lesen |
4 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 45,300 | +1,48 % | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions | Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus... ► Artikel lesen | |
| JANUX THERAPEUTICS | 53,54 | +1,98 % | Janux Therapeutics CEO David Campbell verkauft Aktien im Wert von 1,4 Millionen US-Dollar | ||
| TEMPUS AI | 33,760 | 0,00 % | Cathie Woods ARK kauft AMD und TEMPUS AI, verkauft ARCHER AVIATION | ||
| QUANTUM-SI | 2,690 | 0,00 % | Pre-market Movers: Intrusion, SES AI, Solid Power, Quantum-Si, Rail Vision | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green Intrusion Inc. (INTZ) is up over 380% at $2.16.
SES... ► Artikel lesen | |
| HUMACYTE | 5,050 | 0,00 % | Humacyte (NASDAQ:HUMA) Shares Up 6% - Here's What Happened | ||
| RECURSION PHARMACEUTICALS | 6,765 | 0,00 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 76,96 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome | Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those... ► Artikel lesen | |
| IMMUNOVANT | 24,770 | +3,73 % | Immunovant stock hits 52-week low at $24.61 amid market challenges | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 54,15 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody sonelokimab in patients with active psoriatic arthritis | MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
Two trials for active psoriatic arthritis (PsA) with one focusing... ► Artikel lesen | |
| KEROS THERAPEUTICS | 15,830 | 0,00 % | Keros Therapeutics-Aktie erreicht 52-Wochen-Tief bei 15,67 US-Dollar | ||
| OLEMA PHARMACEUTICALS | 5,830 | +3,92 % | Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium | Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with... ► Artikel lesen | |
| THIRD HARMONIC BIO | 10,290 | -0,87 % | Third Harmonic Bio Announces Third Quarter 2024 Financial Results | THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN FRANCISCO... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 55,38 | 0,00 % | Tarsus Pharmaceuticals-Aktie erreicht 52-Wochen-Hoch von 56,84 US-Dollar | ||
| ARS PHARMACEUTICALS | 10,550 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates | Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive... ► Artikel lesen | |
| ARCELLX | 76,86 | -1,90 % | Arcellx Stock Earns 82 Relative Strength Rating |
Das Unternehmen INTEGRAGEN kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,460 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTEGRAGEN finden Sie auf Wallstreet Online.
